PFIZER has entered into a series of agreements with Aurobindo Pharma to market medicines that are no longer patent protected and don’t have...

Ranbaxy has settled most of its patent disputes with Pfizer, allowing it to launch a generic version of Lipitor from November 30, 2011. Ran...

Pfizer has filed two separate patent infringement cases against Ranbaxy in a bid to extend the exclusivity of its $13-billion anti-choleste...

There is no quick remedy for what ails the pharmaceutical industry: a tougher environment for drug approvals and a dwindling pipeline of ne...

Apart from plant shutdowns, the company plans to lay off about 4,300 employees in a broad restructuring aimed at cost savings of $1.5 b by ...

Wockhardt has launched Amlodipine tablets in US market. The tablets are in strengths of 2.5 mg, 5 mg and 10 mg. The US market for Amlodipin...

The company's Amlodipine Besylate tablets are AB-rated generic equivalent of Pfizer's Norvasc tablets.

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories, has received tentative approval from the U.S. Food a...

Mylan Laboratories agreed to buy Merck KGaA’s generic-drug unit for 4.9 billion euros ($6.7 billion) in cash to become the world’s third-la...

Indian generic pharma companies may now find it easier to challenge patents in the US. In another twist in the battle between innovators an...

Ranbaxy has said the company will challenge the litigation filed by Pfizer, the world’s largest drug maker.